Metraipolis › archive › dc_ef0870c3ee45
ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma — Europe PMC PMID:42328676
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42328676
- DOI
- 10.7717/peerj.21347
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T08:56:02.498Z
- SHA-256 of the archived text
78859b4116a1c9cb69fe329c891a5ce7f8368bc4a316a060ade22477a1a43054- Stable URL of this page
https://metraipolis.com/documento/dc_ef0870c3ee45
How to cite
ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma — Europe PMC PMID:42328676 — Europe PMC (en), https://europepmc.org/article/MED/42328676 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ef0870c3ee45 (Metraipolis archive dc_ef0870c3ee45, sha256 78859b4116a1c9cb69fe329c891a5ce7f8368bc4a316a060ade22477a1a43054)
BibTeX
@misc{dcef0870c3ee45,
title = {ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma — Europe PMC PMID:42328676},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42328676},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ef0870c3ee45; sha256 78859b4116a1c9cb69fe329c891a5ce7f8368bc4a316a060ade22477a1a43054},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42328676. Agents can read the archived copy with the MCP tool read_document.